Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.
Demierre
Marie-France
MF
Taverna
Josephine
J
D000588:Amines / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications*; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D009182:Mycosis Fungoides / Q000150:complications; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D012751:Sezary Syndrome / Q000150:complications; D012878:Skin Neoplasms / Q000150:complications*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D000588:Amines; D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D003509:Cyclohexanecarboxylic Acids; D008803:Mianserin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000078785:Mirtazapine